Literature DB >> 18342582

Determination of voriconazole in human plasma and saliva using high-performance liquid chromatography with fluorescence detection.

Claudia Michael1, Jens Teichert, Rainer Preiss.   

Abstract

Voriconazole is a widely used triazole antifungal agent with a broad spectrum including Aspergillus species. A simple, sensitive and selective high-performance liquid chromatography method for the determination of voriconazole in human plasma and saliva was developed. Drug and internal standard (UK-115 794) were extracted from alkaline plasma and saliva with n-hexane-ethyl acetate (3:1, v/v) and analyzed on a Luna C 18 column with fluorimetric detection set at excitation and emission wavelengths of 254 and 372 nm, respectively. The calibration curve was linear through the range of 0.1-10 microg/ml using a 0.3 ml sample volume. The intra- and inter-day precisions were all below 6.1% for plasma and below 9.1% for saliva. Accuracies ranged from 94 to 109% for both matrices. Mean recovery was 86+/-4% for voriconazole. The method showed acceptable values for precision, recovery and sensitivity and is well suited for routine analysis work and for pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18342582     DOI: 10.1016/j.jchromb.2008.02.009

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  8 in total

1.  Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.

Authors:  Lorena Baietto; Antonio D'Avolio; Giusi Ventimiglia; Francesco Giuseppe De Rosa; Marco Siccardi; Marco Simiele; Mauro Sciandra; Giovanni Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

2.  Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer?

Authors:  Janet Hardy; Ross Norris; Helen Anderson; Angela O'Shea; Bruce Charles
Journal:  Support Care Cancer       Date:  2011-04-15       Impact factor: 3.603

3.  Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography.

Authors:  Kathrin Kahle; Peter Langmann; Diana Schirmer; Ulrike Lenker; Daniela Keller; Annegret Helle; Hartwig Klinker; Werner J Heinz
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

4.  Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.

Authors:  Claudia Michael; Uta Bierbach; Katrin Frenzel; Thoralf Lange; Nadezda Basara; Dietger Niederwieser; Christine Mauz-Körholz; Rainer Preiss
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

5.  Development and Validation of Voriconazole Concentration by LC-MS-MS: Applied in Clinical Implementation.

Authors:  Santirat Prommas; Apichaya Puangpetch; Nuttawut Jenjirattithigarn; Sumonrat Chuwongwattana; Thawinee Jantararoungtong; Napatrupron Koomdee; Siwalee Santon; Montri Chamnanphon; Chonlaphat Sukasem
Journal:  J Clin Lab Anal       Date:  2016-06-24       Impact factor: 2.352

6.  Analysis of imidazoles and triazoles in biological samples after MicroExtraction by packed sorbent.

Authors:  Cristina Campestre; Marcello Locatelli; Paolo Guglielmi; Elisa De Luca; Giuseppe Bellagamba; Sergio Menta; Gokhan Zengin; Christian Celia; Luisa Di Marzio; Simone Carradori
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

Review 7.  Assessment of greenness for the determination of voriconazole in reported analytical methods.

Authors:  Hemanth Kumar Chanduluru; Abimanyu Sugumaran
Journal:  RSC Adv       Date:  2022-02-28       Impact factor: 3.361

8.  Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats.

Authors:  Ji-Sang Lee; Hyo-Sung Kim; Yong-Seob Jung; Hyeon-Gyeom Choi; So-Hee Kim
Journal:  Pharmaceutics       Date:  2021-05-18       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.